Pertussis Vaccine Market Size, Share, Growth, and Industry Analysis, By Types (Acellular Vaccines, Whole-cell Vaccines), By Applications (12 Months Below, 12 Months Above) , and Regional Insights and Forecast to 2035

Pertussis Vaccine Market Size

The Global Pertussis Vaccine Market was valued at USD 5.6 billion in 2025 and is projected to reach USD 5.75 billion in 2026. The market is further expected to grow to USD 5.89 billion in 2027 and reach USD 7.18 billion by 2035, registering a CAGR of 2.51% during the forecast period 2026-2035. Growing vaccination coverage, expanding immunization programs, and increasing awareness about infectious disease prevention continue to support market growth. More than 80% vaccination coverage in many countries and booster adoption rates above 50% are contributing to steady market expansion.

The US Pertussis Vaccine Market continues to show stable growth due to strong public immunization programs and high healthcare awareness. Childhood vaccination coverage remains above 90%, while booster dose participation among adolescents and adults exceeds 55% in several healthcare systems. More than 65% of healthcare providers actively recommend pertussis booster vaccination. Maternal vaccination participation has crossed 60%, helping improve infant protection rates. Increasing focus on preventive healthcare, combined with improved vaccine tracking systems used by over 70% of healthcare facilities, continues to strengthen the US Pertussis Vaccine Market.

Key Findings

• Market Size: Global Pertussis Vaccine Market reached USD 5.6 billion in 2025, USD 5.75 billion in 2026, and USD 7.18 billion by 2035 at 2.51% CAGR.
• Growth Drivers: Vaccination coverage exceeds 80%, maternal vaccine adoption surpasses 60%, booster participation approaches 55%, and preventive healthcare awareness exceeds 70%.
• Trends: Acellular vaccine usage exceeds 70%, combination vaccine preference surpasses 75%, digital monitoring adoption reaches 55%, and booster awareness exceeds 50%.
• Key Players: Sanofi Pasteur, GSK, Mitsubishi Tanabe Pharma, Walvax Biotechnology, Wuhan Institute of Biological Products & more.
• Regional Insights: North America 34%, Europe 29%, Asia-Pacific 27%, Middle East & Africa 10%, supported by expanding vaccination coverage and healthcare access.
• Challenges: Vaccine hesitancy affects 20% to 30% populations, booster compliance remains below 50%, and missed immunization schedules exceed 15%.
• Industry Impact: More than 70% immunization programs support vaccine demand, while over 65% healthcare institutions prioritize preventive vaccination strategies.
• Recent Developments: Manufacturing efficiency improved by 15%, distribution performance increased 18%, digital tracking adoption rose 20%, and quality systems improved 12%.

The Pertussis Vaccine Market remains an important part of global immunization programs because pertussis continues to affect infants, children, and adults. Acellular vaccines account for more than 70% of total vaccine use due to their improved safety profile. Over 80% of routine childhood vaccination schedules include pertussis protection, while maternal vaccination participation exceeds 60% in several regions. Combination vaccines are preferred by more than 75% of healthcare providers because they improve compliance and reduce the number of injections. Expanding booster vaccination programs and growing awareness continue to support long-term demand across the market.

Pertussis Vaccine Market Trends

The Pertussis Vaccine Market is witnessing steady growth due to increasing awareness about preventive healthcare, stronger immunization programs, and growing focus on infant and maternal vaccination. Public health agencies across multiple regions continue to expand vaccine coverage, helping improve protection against pertussis infections. In many countries, childhood immunization coverage for pertussis vaccines remains above 80%, while several developed healthcare systems report coverage levels exceeding 90%. Maternal vaccination programs have also expanded, with participation rates in some regions crossing 60%, supporting newborn protection during early life stages.

Combination vaccines are becoming more popular in the Pertussis Vaccine Market, with healthcare providers favoring vaccines that protect against multiple diseases through a single dose. More than 70% of pediatric vaccination schedules now include combination vaccine products, reducing the number of injections required. Acellular pertussis vaccines continue to dominate usage, accounting for over 75% of administered pertussis vaccine doses in many healthcare systems due to their improved safety profile. In addition, awareness campaigns have increased vaccine acceptance, with some regions reporting public confidence levels above 65%.

The Pertussis Vaccine Market is also benefiting from rising vaccination rates among adolescents and adults. Booster dose adoption has increased significantly, with coverage levels approaching 50% in several high-income regions. Healthcare authorities are focusing on reducing outbreaks through expanded booster programs, especially among healthcare workers, pregnant women, and older adults. Digital vaccine tracking systems now support more than 55% of immunization monitoring activities in advanced healthcare networks, improving compliance and follow-up rates. These developments continue to strengthen demand across the global Pertussis Vaccine Market.

Pertussis Vaccine Market Dynamics

OPPORTUNITY

"Expansion of Maternal and Adult Immunization Programs"

The Pertussis Vaccine Market has strong opportunities through the expansion of maternal and adult vaccination programs. Healthcare organizations continue to encourage vaccination during pregnancy, with adoption rates in several regions surpassing 60%. Studies indicate that maternal immunization can reduce infant pertussis cases by more than 70%, improving early-life protection. Adult booster vaccination programs are also growing, with participation levels approaching 50% in some developed healthcare systems. More than 65% of healthcare professionals support broader adult immunization policies, while over 55% of vaccination campaigns now include awareness activities focused on booster doses. These factors create significant opportunities for manufacturers and healthcare providers within the Pertussis Vaccine Market.

DRIVERS

"Rising Demand for Preventive Healthcare and Routine Immunization"

A major driver of the Pertussis Vaccine Market is the growing focus on preventive healthcare and routine vaccination programs. Childhood immunization coverage exceeds 80% across many countries, while several national vaccination initiatives maintain coverage levels above 90%. Public awareness regarding vaccine-preventable diseases has improved significantly, with health education campaigns reaching more than 70% of targeted populations in many regions. Combination vaccines are preferred by over 70% of healthcare providers due to convenience and improved compliance. Furthermore, more than 60% of parents actively seek information about vaccine schedules, supporting continued demand for pertussis vaccines and contributing to wider vaccine adoption.

RESTRAINTS

"Concerns Regarding Vaccine Hesitancy and Public Perception"

Vaccine hesitancy remains a restraint for the Pertussis Vaccine Market despite ongoing awareness efforts. Surveys in several regions indicate that nearly 20% to 30% of individuals express concerns regarding vaccine safety, effectiveness, or side effects. In some communities, misinformation affects vaccination decisions, leading to lower participation rates. Reports suggest that missed vaccination appointments can account for more than 15% of incomplete immunization schedules. Additionally, healthcare access limitations influence vaccine uptake in certain rural and underserved areas, where coverage levels may remain below national averages. These factors can slow vaccination expansion and create barriers for broader market penetration.

CHALLENGE

"Maintaining Long-Term Immunity and Booster Compliance"

One of the key challenges facing the Pertussis Vaccine Market is maintaining long-term immunity and ensuring booster dose compliance. Research indicates that immunity levels may gradually decline over time, increasing the need for booster vaccinations among adolescents and adults. However, booster coverage in many regions remains below 50%, creating gaps in population protection. More than 25% of eligible adults may miss recommended booster schedules, while awareness regarding adult pertussis vaccination remains lower than childhood vaccination awareness. Healthcare providers continue to face challenges in improving follow-up rates, monitoring compliance, and increasing participation among high-risk groups, making booster management an important challenge for the market.

Segmentation Analysis

The Pertussis Vaccine Market is segmented by type and application, with each segment playing an important role in disease prevention programs. The market was valued at USD 5.6 Billion in 2025 and reached USD 5.75 Billion in 2026. It is expected to reach USD 7.18 Billion by 2035. Acellular vaccines account for a significant share due to their improved safety profile and wide use in national immunization programs. Whole-cell vaccines continue to be used in several developing regions because of their cost efficiency. By application, both infants below 12 months and individuals above 12 months contribute to vaccine demand. Increasing immunization coverage, growing booster dose programs, and rising awareness of preventive healthcare continue to support growth across all segments of the Pertussis Vaccine Market.

By Type

Acellular Vaccines

Acellular vaccines are widely used due to lower rates of adverse reactions and strong acceptance among healthcare providers. More than 70% of vaccination programs in developed healthcare systems prefer acellular formulations. These vaccines are commonly included in combination vaccine schedules, helping improve compliance rates by over 60%. Their use is especially high among infants, children, and pregnant women because of their favorable safety profile and effectiveness in reducing disease transmission.

Acellular Vaccines held the largest share in the Pertussis Vaccine Market, accounting for USD 3.97 Billion in 2025, representing 71% of the total market. This segment is expected to grow at a CAGR of 2.8% from 2025 to 2035, supported by strong immunization programs, booster dose adoption, and increasing public awareness.

Whole-cell Vaccines

Whole-cell vaccines remain important in several countries where large-scale immunization programs require cost-effective solutions. These vaccines continue to support public health campaigns and account for a substantial portion of vaccine doses distributed in developing healthcare systems. Nearly 40% of public vaccination initiatives in low-cost healthcare environments still include whole-cell formulations because of their broad availability and established use.

Whole-cell Vaccines accounted for USD 1.63 Billion in 2025, representing 29% of the total market. This segment is projected to expand at a CAGR of 1.8% from 2025 to 2035, supported by government-supported immunization programs and continued demand from developing regions.

By Application

12 Months Below

The 12 Months Below segment represents a major area of vaccine administration because infants face a higher risk of severe pertussis infection. More than 75% of routine childhood immunization schedules include pertussis vaccine doses during the first year of life. Vaccination coverage in this age group exceeds 80% in many countries, supported by national healthcare programs and parental awareness campaigns. Continuous focus on infant health keeps this segment important for vaccine demand.

12 Months Below accounted for USD 3.45 Billion in 2025, representing 61.5% of the total market. This segment is anticipated to grow at a CAGR of 2.7% from 2025 to 2035, supported by strong infant immunization coverage and expanding healthcare access.

12 Months Above

The 12 Months Above segment includes booster vaccinations for children, adolescents, adults, and pregnant women. Booster vaccination awareness has improved significantly, with participation levels approaching 50% in several developed healthcare systems. Healthcare organizations continue to promote additional vaccine doses to strengthen immunity and reduce disease outbreaks. Growing public health campaigns and better vaccine tracking systems are helping improve compliance within this application segment.

12 Months Above accounted for USD 2.15 Billion in 2025, representing 38.5% of the total market. This segment is expected to grow at a CAGR of 2.2% from 2025 to 2035, driven by rising booster dose programs and increased awareness among adult populations.

Pertussis Vaccine Market Regional Outlook

The Pertussis Vaccine Market demonstrates steady expansion across North America, Europe, Asia-Pacific, and Middle East & Africa. The market reached USD 5.75 Billion in 2026 and is projected to attain USD 7.18 Billion by 2035. North America accounts for 34% of the market share, followed by Europe with 29%, Asia-Pacific with 27%, and Middle East & Africa with 10%. Rising vaccination awareness, government-supported immunization programs, improved healthcare infrastructure, and growing booster dose adoption continue to support market development across all regions.

North America

North America represents 34% of the global Pertussis Vaccine Market. Childhood vaccination coverage exceeds 90% across several healthcare systems, while adult booster participation approaches 55%. More than 70% of healthcare providers recommend booster doses for adolescents and adults. Maternal vaccination programs continue to expand, with participation levels exceeding 60% in many areas. Public awareness campaigns and advanced immunization tracking systems contribute to higher vaccine compliance rates and support sustained market demand.

North America accounted for USD 1.96 Billion in 2026, representing 34% of the global market share. Strong vaccination coverage and established healthcare infrastructure continue to support regional growth.

Europe

Europe holds 29% of the Pertussis Vaccine Market. More than 85% of children receive routine pertussis vaccinations through national healthcare programs. Combination vaccines account for over 70% of administered doses in several countries. Booster vaccination awareness continues to improve, with adult coverage exceeding 45% in many healthcare systems. Public health authorities remain focused on maintaining high immunization rates and reducing outbreak risks through expanded vaccination initiatives.

Europe accounted for USD 1.67 Billion in 2026, representing 29% of the global market share. Continued government support and strong healthcare access remain important growth factors.

Asia-Pacific

Asia-Pacific accounts for 27% of the global Pertussis Vaccine Market. The region benefits from large birth populations and expanding immunization coverage. More than 80% of infants receive pertussis vaccines through public vaccination programs in major countries. Awareness initiatives and healthcare investments continue to improve vaccine accessibility. Demand for both acellular and whole-cell vaccines remains strong, supporting widespread adoption across urban and rural healthcare systems.

Asia-Pacific accounted for USD 1.55 Billion in 2026, representing 27% of the global market share. Growing healthcare infrastructure and increasing vaccine awareness continue to strengthen market expansion.

Middle East & Africa

Middle East & Africa contributes 10% of the Pertussis Vaccine Market. Government immunization programs continue to improve vaccine access across several countries. Childhood vaccination coverage exceeds 70% in many healthcare systems, while awareness campaigns have increased participation in routine immunization schedules. International healthcare partnerships and public health initiatives support vaccination outreach activities. Demand remains strong as healthcare providers focus on reducing preventable infectious diseases through broader vaccine coverage.

Middle East & Africa accounted for USD 0.58 Billion in 2026, representing 10% of the global market share. Expanding healthcare services and improved immunization access continue to support market development.

List of Key Pertussis Vaccine Market Companies Profiled

Investment Analysis and Opportunities in Pertussis Vaccine Market

Investment activity within the Pertussis Vaccine Market continues to increase as healthcare organizations focus on disease prevention and immunization expansion. More than 65% of vaccine manufacturers are investing in advanced production technologies to improve efficiency and supply reliability. Nearly 58% of ongoing vaccine development projects focus on combination vaccines that simplify immunization schedules. Public health investments support expanded vaccination coverage, with over 70% of healthcare authorities prioritizing preventive healthcare initiatives. Maternal vaccination programs now contribute to more than 40% of newly launched awareness campaigns. Around 55% of healthcare institutions are investing in digital immunization tracking systems to improve compliance rates. These trends create opportunities for vaccine innovation, manufacturing expansion, and improved healthcare access throughout the Pertussis Vaccine Market.

New Products Development

New product development remains a key focus area within the Pertussis Vaccine Market. More than 60% of current research efforts target improved acellular vaccine formulations with enhanced immune response profiles. Combination vaccine development represents over 50% of new vaccine projects, helping reduce the number of required injections. Nearly 45% of manufacturers are working on next-generation vaccine technologies designed to improve long-term protection. Advanced manufacturing techniques have improved production efficiency by approximately 30% in several facilities. Research programs also focus on increasing vaccine stability and distribution efficiency. Growing interest in maternal and adult vaccination has encouraged companies to develop products tailored for broader population groups, supporting future market expansion.

Developments

• Sanofi Pasteur: Expanded vaccine manufacturing capabilities and improved production efficiency, increasing output capacity by more than 15%. The development supports broader vaccine availability and strengthens supply chain stability across multiple healthcare markets.
• GSK: Enhanced its vaccine distribution network through digital tracking systems that improved supply monitoring by nearly 20%. The initiative supports better inventory management and improved vaccine accessibility.
• Walvax Biotechnology: Advanced research activities focused on acellular vaccine improvements. Internal development programs reported enhanced immune response indicators and increased manufacturing consistency exceeding 10%.
• KM Biologics: Strengthened quality control processes across vaccine production facilities. Process improvements increased operational efficiency by approximately 12% while supporting higher product reliability standards.
• Chengdu Institute of Biological Products: Expanded public immunization support programs and improved production management systems. Distribution performance improved by nearly 18%, helping increase vaccine availability in target healthcare regions.

Report Coverage

The Pertussis Vaccine Market report provides detailed coverage of market structure, industry trends, segmentation, regional performance, competitive landscape, investment activity, and future opportunities. The study evaluates strengths, weaknesses, opportunities, and threats across the industry. Strong vaccination coverage exceeding 80% in many regions represents a major market strength. Increasing use of combination vaccines, accounting for more than 70% of several immunization programs, further supports market development.

From a weakness perspective, vaccine hesitancy affects approximately 20% to 30% of certain populations, creating challenges for broader coverage. Booster compliance remains below optimal levels in several healthcare systems, reducing long-term protection rates. Opportunities continue to emerge through maternal vaccination programs, which have expanded participation beyond 60% in some regions. Adult immunization campaigns also create growth potential as awareness levels continue to improve.

Threats include supply chain disruptions, regulatory complexities, and changing public perceptions regarding vaccination. Despite these challenges, more than 65% of healthcare organizations continue to prioritize preventive healthcare programs. The report covers key manufacturers, product categories, application areas, and regional developments while providing detailed analysis of demand patterns, vaccination coverage rates, market share distribution, and competitive positioning throughout the Pertussis Vaccine Market.

Future Scope

The future scope of the Pertussis Vaccine Market remains positive as healthcare systems continue to emphasize preventive healthcare and disease control strategies. More than 75% of national immunization programs are expected to maintain strong support for routine pertussis vaccination. Expanding maternal vaccination initiatives may further improve infant protection rates, while adult booster campaigns are expected to increase participation beyond current levels.

Combination vaccines are likely to remain a major growth area, with more than 70% of healthcare providers preferring products that reduce the number of injections. Digital immunization tracking systems are projected to support over 60% of vaccination monitoring activities, helping improve compliance and follow-up rates. Research investments focused on enhanced vaccine formulations continue to increase, with more than 50% of development projects targeting improved protection and vaccine convenience.

Healthcare awareness programs are expected to reach broader populations, improving vaccination acceptance and reducing missed immunization opportunities. Emerging healthcare markets continue to expand vaccine access through public immunization initiatives and infrastructure improvements. Increased focus on disease prevention, vaccine innovation, and healthcare accessibility is expected to support sustained development across the Pertussis Vaccine Market. Growing public health investments, broader vaccination coverage, and stronger immunization strategies will continue to create opportunities for manufacturers, healthcare providers, and public health organizations over the coming years.

Pertussis Vaccine Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 5.6 Billion in 2026
Market Size Value By	USD 7.18 Billion by 2035
Growth Rate	CAGR of 2.51% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Acellular Vaccines Whole-cell Vaccines By Application : 12 Months Below 12 Months Above
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample

Frequently Asked Questions

• What value is the Pertussis Vaccine Market expected to touch by 2035?

  The global Pertussis Vaccine Market is expected to reach USD 7.18 Billion by 2035.

• What CAGR is the Pertussis Vaccine Market expected to exhibit by 2035?

  The Pertussis Vaccine Market is expected to exhibit a CAGR of 2.51% by 2035.

• Who are the top players in the Pertussis Vaccine Market?

  Sanofi Pasteur, GSK, Mitsubishi Tanabe Pharma, Wuhan Institute of Biological Products, Walvax Biotechnology, Minhai Biotechnology, KM Biologics, Chengdu Institute of Biological Products

• What was the value of the Pertussis Vaccine Market in 2025?

  In 2025, the Pertussis Vaccine Market value stood at USD 5.6 Billion.

Related Reports

Npwt Devices Market